CONSORT and clinical trial reporting: room for improvement

Heddle, Nancy M.; Ness, Paul M.

doi:10.1111/trf.13539

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Cazenave [15] and Lozano groups [16] found no significant differences in the clinical effectiveness of PI-treated versus untreated PCs. Differences in data collection methods make it difficult to compare studies, so the clinical relevance of PITs in platelet function remains unclear in terms of CCI and bleeding time [17,18]. To summarize, there is a general consensus that PITs have a negative impact on the in vitro characteristics of PCs, but the reasons are not completely known or understood.…”

Section: Introductionmentioning

confidence: 99%

Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion

Sonego

Abonnenc

Tissot

et al. 2017

IJMS

View full text Add to dashboard Cite

Blood banks use pathogen inactivation (PI) technologies to increase the safety of platelet concentrates (PCs). The characteristics of PI-treated PCs slightly differ from those of untreated PCs, but the underlying reasons are not well understood. One possible cause is the generation of oxidative stress during the PI process. This is of great interest since reactive oxygen species (ROS) act as second messengers in platelet functions. Furthermore, there are links between protein oxidation and phosphorylation, another mechanism that is critical for cell regulation. Current research efforts focus on understanding the underlying mechanisms and identifying new target proteins. Proteomics technologies represent powerful tools for investigating signaling pathways involving ROS and post-translational modifications such as phosphorylation, while quantitative techniques enable the comparison of the platelet resting state versus the stimulated state. In particular, redox cysteine is a key player in platelet activation upon stimulation by different agonists. This review highlights the experiments that have provided insights into the roles of ROS in platelet function and the implications for platelet transfusion, and potentially in diseases such as inflammation and platelet hyperactivity. The review also describes the implication of redox mechanism in platelet storage considerations.

show abstract